Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke

References

• Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study GroupN Engl J Med1995333158115877477192
   PubMed Web of Science ®Google Scholar
• AdamsHPJrBrottTGFurlanAJGuidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a special writing group of the stroke council, American Heart AssociationStroke199627171117188784157
   PubMed Web of Science ®Google Scholar
• Practice advisory: thrombolytic therapy for acute ischemic stroke – summary statement. Report of the Quality Standards Subcommittee of the American Academy of NeurologyNeurology1996478358398797492
   PubMed Web of Science ®Google Scholar
• American College of Emergency PhysiciansAmerican Academy of NeurologyClinical policy: use of intravenous tPA for the management of acute ischemic stroke in the emergency departmentAnn Emerg Med20136122524323331647
   PubMedGoogle Scholar
• GoASMozaffarianDRogerVLHeart disease and stroke statistics – 2013 update: a report from the American Heart AssociationCirculation2013127e6e24523239837
   PubMed Web of Science ®Google Scholar
• FonarowGCSmithEESaverJLImproving door-to-needle times in acute ischemic stroke: the design and rationale for the American Heart Association/American Stroke Association’s Target: Stroke initiativeStroke2011422983298921885841
   PubMed Web of Science ®Google Scholar
• CaplanLRMohrJPKistlerJPKoroshetzWShould thrombolytic therapy be the first-line treatment for acute ischemic stroke? Thrombolysis – not a panacea for ischemic strokeN Engl J Med199733713091310 discussion 13139345084
   PubMed Web of Science ®Google Scholar
• FirstenbergMSThrombolytic therapy in acute ischemic strokeN Engl J Med199733666 author reply 66–678984334
   PubMedGoogle Scholar
• ClarkWMLydenPDMaddenKPZivinJAThrombolytic therapy in acute ischemic strokeN Engl J Med19973366566 author reply 66–678984333
   PubMedGoogle Scholar
• FrankelMRThrombolytic therapy in acute ischemic strokeN Engl J Med199733665 author reply 66–678984332
   PubMedGoogle Scholar
• KirshnerHSShould thrombolytic therapy be the first-line treatment for acute ischemic stroke?N Engl J Med1998338761762 author reply 762–7639499171
   PubMedGoogle Scholar
• LevinBThompsonJLChakrabortyBLevyGMacArthurRHaleyECStatistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in acute ischemic stroke: an efficient, dose-adaptive, seamless Phase II/III designClin Trials2011839840721737464
   PubMed Web of Science ®Google Scholar
• HackeWFurlanAJAl-RawiYIntravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled studyLancet Neurol2009814115019097942
   PubMed Web of Science ®Google Scholar
• HackeWAlbersGAl-RawiYThe Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplaseStroke200536667315569863
   PubMed Web of Science ®Google Scholar
• del ZoppoGJPoeckKPessinMSRecombinant tissue plasminogen activator in acute thrombotic and embolic strokeAnn Neurol19923278861642475
   PubMed Web of Science ®Google Scholar
• BrottTGHaleyECJrLevyDEUrgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutesStroke1992236326401579958
   PubMed Web of Science ®Google Scholar
• HaleyECJrLevyDEBrottTGUrgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91–180 minutes from onsetStroke1992236416451579959
   PubMed Web of Science ®Google Scholar
• MoriEYonedaYTabuchiMIntravenous recombinant tissue plasminogen activator in acute carotid artery territory strokeNeurology1992429769821579252
   PubMed Web of Science ®Google Scholar
• ClarkWMAlbersGWMaddenKPHamiltonSThe rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigatorsStroke20003181181610753980
   PubMed Web of Science ®Google Scholar
• HackeWKasteMFieschiCIntravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)JAMA1995274101710257563451
   PubMed Web of Science ®Google Scholar
• BrottTAdamsHPJrOlingerCPMeasurements of acute cerebral infarction: a clinical examination scaleStroke1989208648702749846
   PubMed Web of Science ®Google Scholar
• BrownDLJohnstonKCWagnerDPHaleyECJrPredicting major neurological improvement with intravenous recombinant tissue plasminogen activator treatment of strokeStroke20043514715014657446
   PubMed Web of Science ®Google Scholar
• HaleyECJrLewandowskiCTilleyBCMyths regarding the NINDS rt-PA Stroke Trial: setting the record straightAnn Emerg Med1997306766829360581
   PubMed Web of Science ®Google Scholar
• DonnanGADavisSMChambersBRStreptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study GroupJAMA19962769619668805730
   PubMed Web of Science ®Google Scholar
• HortonRMAST-I: agreeing to disagree. Multicentre Acute Stroke Trial – Italy GroupLancet199534615047491039
   PubMed Web of Science ®Google Scholar
• AlbersGWClarkWMMaddenKPHamiltonSAATLANTIS trial: results for patients treated within 3 hours of stroke onset. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic StrokeStroke20023349349511823658
   PubMed Web of Science ®Google Scholar
• HackeWBluhmkiESteinerTDichotomized efficacy end points and global end-point analysis applied to the ECASS intention-to-treat data set: post hoc analysis of ECASS IStroke199829207320759756584
   PubMed Web of Science ®Google Scholar
• WardlawJMMurrayVBergeEDel ZoppoGJThrombolysis for acute ischaemic strokeCochrane Database Syst Rev20094CD00021319821269
   PubMed Web of Science ®Google Scholar
• HackeWKasteMFieschiCRandomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study InvestigatorsLancet1998352124512519788453
   PubMed Web of Science ®Google Scholar
• RinglebPASchellingerPDSchranzCHackeWThrombolytic therapy within 3 to 6 hours after onset of ischemic stroke: useful or harmful?Stroke2002331437144111988629
   PubMed Web of Science ®Google Scholar
• MaHParsonsMWChristensenSA multicentre, randomized, double-blinded, placebo-controlled Phase III study to investigate EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND)Int J Stroke20127748022188854
   PubMed Web of Science ®Google Scholar
• HackeWDonnanGFieschiCAssociation of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trialsLancet200436376877415016487
   PubMed Web of Science ®Google Scholar
• HackeWKasteMBluhmkiEThrombolysis with alteplase 3 to 4.5 hours after acute ischemic strokeN Engl J Med20083591317132918815396
   PubMed Web of Science ®Google Scholar
• JauchECSaverJLAdamsHPJrGuidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke AssociationStroke20134487094723370205
   PubMed Web of Science ®Google Scholar
• BaronJCvon KummerRdel ZoppoGJTreatment of acute ischemic stroke. Challenging the concept of a rigid and universal time windowStroke199526221922217491639
   PubMed Web of Science ®Google Scholar
• AzzimondiGBasseinLFioraniLVariables associated with hospital arrival time after stroke: effect of delay on the clinical efficiency of early treatmentStroke1997285375429056608
   PubMed Web of Science ®Google Scholar
• LevyDEBrottTGHaleyECJrFactors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic strokeStroke1994252912978303734
   PubMed Web of Science ®Google Scholar
• MarlerJRTilleyBCLuMEarly stroke treatment associated with better outcome: the NINDS rt-PA stroke studyNeurology2000551649165511113218
   PubMed Web of Science ®Google Scholar
• SaverJLTime is brain – quantifiedStroke20063726326616339467
   PubMed Web of Science ®Google Scholar
• SaverJLFonarowGCSmithEETime to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic strokeJAMA20133092480248823780461
   PubMed Web of Science ®Google Scholar
• FonarowGCSmithEESaverJLTimeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutesCirculation201112375075821311083
   PubMed Web of Science ®Google Scholar
• LimanTGWinterBWaldschmidtCTelestroke ambulances in prehospital stroke management: concept and pilot feasibility studyStroke2012432086209022693132
   PubMed Web of Science ®Google Scholar
• MeretojaAStrbianDMustanojaSTatlisumakTLindsbergPJKasteMReducing in-hospital delay to 20 minutes in stroke thrombolysisNeurology20127930631322622858
   PubMed Web of Science ®Google Scholar
• O’GaraPTKushnerFGAscheimDD2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice GuidelinesCirculation2013127e362e42523247304
   PubMed Web of Science ®Google Scholar
• HillMDLyeTMossHHemi-orolingual angioedema and ace inhibition after alteplase treatment of strokeNeurology2003601525152712743244
   PubMed Web of Science ®Google Scholar
• PessinMSDel ZoppoGJEstolCJThrombolytic agents in the treatment of strokeClin Neuropharmacol1990132712892208179
   PubMed Web of Science ®Google Scholar
• TrouillasPvon KummerRClassification and pathogenesis of cerebral hemorrhages after thrombolysis in ischemic strokeStroke20063755656116397182
   PubMed Web of Science ®Google Scholar
• DerexLNighoghossianNIntracerebral haemorrhage after thrombolysis for acute ischaemic stroke: an updateJ Neurol Neurosurg Psychiatry2008791093109918223014
   PubMed Web of Science ®Google Scholar
• ClarkWMWissmanSAlbersGWJhamandasJHMaddenKPHamiltonSRecombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic StrokeJAMA19992822019202610591384
   PubMed Web of Science ®Google Scholar
• LarrueVvon KummerRRMullerABluhmkiERisk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II)Stroke20013243844111157179
   PubMed Web of Science ®Google Scholar
• HackeWBrottTCaplanLThrombolysis in acute ischemic stroke: controlled trials and clinical experienceNeurology199953S3S1410532643
   PubMed Web of Science ®Google Scholar
• WahlgrenNAhmedNErikssonNMultivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST)Stroke2008393316332218927461
   PubMed Web of Science ®Google Scholar
• StrbianDSairanenTMeretojaAPatient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysisNeurology20117734134821715707
   PubMed Web of Science ®Google Scholar
• SoutherlandAMMalikSJohnstonKCSymptomatic ICH and outcomes in patients after IV tPA: a business of risk or risky business?Neurology20117731531621715703
   PubMed Web of Science ®Google Scholar
• DemchukAMMorgensternLBKriegerDWSerum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic strokeStroke19993034399880385
   PubMed Web of Science ®Google Scholar
• TanneDKasnerSEDemchukAMMarkers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke SurveyCirculation20021051679168511940547
   PubMed Web of Science ®Google Scholar
• SaposnikGDi LeggeSWebsterFHachinskiVPredictors of major neurologic improvement after thrombolysis in acute strokeNeurology2005651169117416247041
   PubMed Web of Science ®Google Scholar
• BatemanBTSchumacherHCBoden-AlbalaBFactors associated with in-hospital mortality after administration of thrombolysis in acute ischemic stroke patients: an analysis of the nationwide inpatient sample 1999 to 2002Stroke20063744044616397164
   PubMed Web of Science ®Google Scholar
• MazyaMEgidoJAFordGAPredicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe implementation of treatments in stroke (SITS) symptomatic intracerebral hemorrhage risk scoreStroke2012431524153122442178
   PubMed Web of Science ®Google Scholar
• Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke TrialStroke199728211921259368551
   PubMed Web of Science ®Google Scholar
• SaverJLDeriving number-needed-to-treat and number-needed-to-harm from the SAINT I trial resultsStroke200738257 author reply 25817185635
   PubMed Web of Science ®Google Scholar
• SaverJLGornbeinJGrottaJNumber needed to treat to benefit and to harm for intravenous tissue plasminogen activator therapy in the 3- to 4.5-hour window: joint outcome table analysis of the ECASS 3 trialStroke2009402433243719498197
   PubMed Web of Science ®Google Scholar
• RabinsteinARundekTPrediction of outcome after ischemic stroke: the value of clinical scoresNeurology201380151623175728
   PubMed Web of Science ®Google Scholar
• DavalosABlancoMPedrazaSThe clinical-DWI mismatch: a new diagnostic approach to the brain tissue at risk of infarctionNeurology2004622187219215210880
   PubMed Web of Science ®Google Scholar
• LansbergMGThijsVNHamiltonSEvaluation of the clinical-diffusion and perfusion-diffusion mismatch models in DEFUSEStroke2007381826183017495217
   PubMed Web of Science ®Google Scholar
• KidwellCSJahanRSaverJLEndovascular treatment for acute ischemic strokeN Engl J Med20133682434243523802241
   PubMedGoogle Scholar
• DavisSMDonnanGAParsonsMWEffects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trialLancet Neurol2008729930918296121
   PubMed Web of Science ®Google Scholar
• BarberPAZhangJDemchukAMHillMDBuchanAMWhy are stroke patients excluded from tPA therapy? An analysis of patient eligibilityNeurology2001561015102011320171
   PubMed Web of Science ®Google Scholar
• KatzanILHammerMDHixsonEDFurlanAJAbou-CheblANadzamDMUtilization of intravenous tissue plasminogen activator for acute ischemic strokeArch Neurol20046134635015023810
   PubMed Web of Science ®Google Scholar
• CochoDBelvisRMarti-FabregasJReasons for exclusion from thrombolytic therapy following acute ischemic strokeNeurology20056471972015728300
   PubMed Web of Science ®Google Scholar
• KleindorferDKisselaBSchneiderAEligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based studyStroke200435e27e2914739423
   PubMed Web of Science ®Google Scholar
• SmithEEFonarowGCReevesMJOutcomes in mild or rapidly improving stroke not treated with intravenous recombinant tissue-type plasminogen activator: findings from Get With The Guidelines – StrokeStroke2011423110311521903949
   PubMed Web of Science ®Google Scholar
• RajajeeVKidwellCStarkmanSEarly MRI and outcomes of untreated patients with mild or improving ischemic strokeNeurology20066798098417000964
   PubMed Web of Science ®Google Scholar
• NedeltchevKSchweglerBHaefeliTOutcome of stroke with mild or rapidly improving symptomsStroke2007382531253517673713
   PubMed Web of Science ®Google Scholar
• BaumannCRBaumgartnerRWGandjourJvon BudingenHCSiegelAMGeorgiadisDGood outcomes in ischemic stroke patients treated with intravenous thrombolysis despite regressing neurological symptomsStroke2006371332133316556881
   PubMed Web of Science ®Google Scholar
• KohrmannMNoweTHuttnerHBSafety and outcome after thrombolysis in stroke patients with mild symptomsCerebrovasc Dis20092716016619092237
   PubMed Web of Science ®Google Scholar
• HassanAEHassanzadehBTohidiVKirmaniJFVery mild stroke patients benefit from intravenous tissue plasminogen activator without increase of intracranial hemorrhageSouth Med J201010339840220375952
   PubMed Web of Science ®Google Scholar
• BluhmkiEChamorroADavalosAStroke treatment with alteplase given 3.0–4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trialLancet Neurol200981095110219850525
   PubMed Web of Science ®Google Scholar
• SaverJLImproving reperfusion therapy for acute ischaemic strokeJ Thromb Haemost20119Suppl 133334321781270
   PubMed Web of Science ®Google Scholar
• KhatriPConawayMRJohnstonKCNinety-day outcome rates of a prospective cohort of consecutive patients with mild ischemic strokeStroke20124356056222052513
   PubMed Web of Science ®Google Scholar
• MariniCBaldassarreMRussoTBurden of first-ever ischemic stroke in the oldest old: evidence from a population-based studyNeurology200462778114718701
   PubMed Web of Science ®Google Scholar
• DerexLNighoghossianNThrombolysis, stroke-unit admission and early rehabilitation in elderly patientsNat Rev Neurol2009550651119652651
   PubMed Web of Science ®Google Scholar
• KammersgaardLPJorgensenHSReithJNakayamaHPedersenPMOlsenTSShort- and long-term prognosis for very old stroke patients. The Copenhagen Stroke StudyAge Ageing20043314915414960430
   PubMed Web of Science ®Google Scholar
• SloanMAPriceTRPetitoCKClinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction: the Thrombolysis in Myocardial Infarction (TIMI) II Pilot and Randomized Clinical Trial combined experienceNeurology1995456496587723950
   PubMed Web of Science ®Google Scholar
• GreenbergSMVonsattelJPDiagnosis of cerebral amyloid angiopathy. Sensitivity and specificity of cortical biopsyStroke199728141814229227694
   PubMed Web of Science ®Google Scholar
• HaleyKEGreenbergSMGurolMECerebral microbleeds and macrobleeds: should they influence our recommendations for antithrombotic therapies?Curr Cardiol Rep20131542524122195
   PubMed Web of Science ®Google Scholar
• TanneDGormanMJBatesVEIntravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older: the tPA stroke survey experienceStroke20003137037510657408
   PubMed Web of Science ®Google Scholar
• MeretojaAPutaalaJTatlisumakTOff-label thrombolysis is not associated with poor outcome in patients with strokeStroke2010411450145820538701
   PubMed Web of Science ®Google Scholar
• SylajaPNCoteRBuchanAMHillMDThrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian alteplase for stroke effectiveness studyJ Neurol Neurosurg Psychiatry20067782682916505004
   PubMed Web of Science ®Google Scholar
• van OostenbruggeRJHuppertsRMLodderJThrombolysis for acute stroke with special emphasis on the very old: experience from a single Dutch centreJ Neurol Neurosurg Psychiatry20067737537716484647
   PubMed Web of Science ®Google Scholar
• EngelterSTBonatiLHLyrerPAIntravenous thrombolysis in stroke patients of > or =80 versus <80 years of age – a systematic review across cohort studiesAge Ageing20063557258017047006
   PubMed Web of Science ®Google Scholar
• MouradianMSSenthilselvanAJicklingGIntravenous rt-PA for acute stroke: comparing its effectiveness in younger and older patientsJ Neurol Neurosurg Psychiatry2005761234123716107357
   PubMed Web of Science ®Google Scholar
• MishraNKAhmedNAndersenGThrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials ArchiveBMJ2010341c604621098614
   PubMed Web of Science ®Google Scholar
• SandercockPWardlawJMLindleyRIThe benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the Third International Stroke Trial [IST-3]): a randomised controlled trialLancet20123792352236322632908
   PubMed Web of Science ®Google Scholar
• HowardGGoffDCPopulation shifts and the future of stroke: forecasts of the future burden of strokeAnn N Y Acad Sci20121268142022994216
   PubMed Web of Science ®Google Scholar
• RudolfJTsivgoulisGDeretziGFeasibility and safety of intravenous thrombolysis for acute ischaemic stroke in northern GreeceInt J Stroke20116919221205250
   PubMed Web of Science ®Google Scholar
• ChernyshevOYMartin-SchildSAlbrightKCSafety of tPA in stroke mimics and neuroimaging-negative cerebral ischemiaNeurology2010741340134520335564
   PubMed Web of Science ®Google Scholar
• WinklerDTFluriFFuhrPThrombolysis in stroke mimics: frequency, clinical characteristics, and outcomeStroke2009401522152519164790
   PubMed Web of Science ®Google Scholar
• ScottPASilbergleitRMisdiagnosis of stroke in tissue plasminogen activator-treated patients: characteristics and outcomesAnn Emerg Med20034261161814581912
   PubMed Web of Science ®Google Scholar
• TsivgoulisGAlexandrovAVChangJSafety and outcomes of intravenous thrombolysis in stroke mimics: a 6-year, single-care center study and a pooled analysis of reported seriesStroke2011421771177421493900
   PubMed Web of Science ®Google Scholar
• GuerreroWRSavitzSITissue-type plasminogen activator for stroke mimics: continuing to be swift rather than delaying treatment to be sureStroke2013441213121423579589
   PubMed Web of Science ®Google Scholar
• HandPJKwanJLindleyRIDennisMSWardlawJMDistinguishing between stroke and mimic at the bedside: the brain attack studyStroke20063776977516484610
   PubMed Web of Science ®Google Scholar
• LibmanRBWirkowskiEAlvirJRaoTHConditions that mimic stroke in the emergency department. Implications for acute stroke trialsArch Neurol199552111911227487564
   PubMed Web of Science ®Google Scholar
• AndersonCSJamrozikKDBurvillPWChakeraTMJohnsonGAStewart-WynneEGAscertaining the true incidence of stroke: experience from the Perth Community Stroke Study, 1989–1990Med J Aust199315880848419780
   PubMed Web of Science ®Google Scholar
• EllekjaerHHolmenJIndredavikBTerentAEpidemiology of stroke in Innherred, Norway, 1994 to 1996. Incidence and 30-day case-fatality rateStroke199728218021849368561
   PubMed Web of Science ®Google Scholar
• ArttoVPutaalaJStrbianDStroke mimics and intravenous thrombolysisAnn Emerg Med201259273222000770
   PubMed Web of Science ®Google Scholar
• ZinkstokSMEngelterSTGensickeHSafety of thrombolysis in stroke mimics: results from a multicenter cohort studyStroke2013441080108423444310
   PubMed Web of Science ®Google Scholar
• Marti-FabregasJBravoYCochoDFrequency and predictors of symptomatic intracerebral hemorrhage in patients with ischemic stroke treated with recombinant tissue plasminogen activator outside clinical trialsCerebrovasc Dis200723859017114877
   PubMed Web of Science ®Google Scholar
• HillMDBuchanAMThrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness StudyCMAJ20051721307131215883405
   PubMed Web of Science ®Google Scholar
• MeschiaJFWilliamsLSFleckJDBrunoABillerJViews on the use of tissue plasminogen activator in acute ischemic stroke: a state-wide survey among neurologists and emergency medicine physicians in IndianaJ Stroke Cerebrovasc Dis1999820721017895166
   PubMedGoogle Scholar
• BrownDLBarsanWGLisabethLDGalleryMEMorgensternLBSurvey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic strokeAnn Emerg Med200546566015988427
   PubMed Web of Science ®Google Scholar
• ShamyMCJaigobinCSThe complexities of acute stroke decision-making: a survey of neurologistsNeurology2013811130113323946306
   PubMed Web of Science ®Google Scholar
• WeintraubMIThrombolysis (tissue plasminogen activator) in stroke: a medicolegal quagmireStroke2006371917192216728683
   PubMed Web of Science ®Google Scholar
• LiangBAZivinJAEmpirical characteristics of litigation involving tissue plasminogen activator and ischemic strokeAnn Emerg Med20085216016418313798
   PubMed Web of Science ®Google Scholar
• CucchiaraBTanneDLevineSRDemchukAMKasnerSA risk score to predict intracranial hemorrhage after recombinant tissue plasminogen activator for acute ischemic strokeJ Stroke Cerebrovasc Dis20081733133318984422
   PubMedGoogle Scholar
• LouMSafdarAMehdirattaMThe HAT score: a simple grading scale for predicting hemorrhage after thrombolysisNeurology2008711417142318955684
   PubMed Web of Science ®Google Scholar
• MenonBKSaverJLPrabhakaranSRisk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activatorStroke2012432293229922811458
   PubMed Web of Science ®Google Scholar
• StrbianDEngelterSMichelPSymptomatic intracranial hemorrhage after stroke thrombolysis: the SEDAN scoreAnn Neurol20127163464122522478
   PubMed Web of Science ®Google Scholar
• StrbianDMeretojaAAhlhelmFJPredicting outcome of IV thrombolysis-treated ischemic stroke patients: the DRAGON scoreNeurology20127842743222311929
   PubMed Web of Science ®Google Scholar
• SaposnikGGuzikAKReevesMOvbiageleBJohnstonSCStroke prognostication using age and NIH Stroke Scale: SPAN-100Neurology201380212823175723
   PubMed Web of Science ®Google Scholar
• SaposnikGFangJKapralMKThe iScore predicts effectiveness of thrombolytic therapy for acute ischemic strokeStroke2012431315132222308252
   PubMed Web of Science ®Google Scholar
• KentDMSelkerHPRuthazerRBluhmkiEHackeWThe stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic strokeStroke2006372957296217068305
   PubMed Web of Science ®Google Scholar
• NtaiosGFaouziMFerrariJLangWVemmosKMichelPAn integer-based score to predict functional outcome in acute ischemic stroke: the ASTRAL scoreNeurology2012781916192222649218
   PubMed Web of Science ®Google Scholar
• ChiuDKriegerDVillar-CordovaCIntravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practiceStroke19982918229445322
   PubMed Web of Science ®Google Scholar
• GrondMStenzelCSchmullingSEarly intravenous thrombolysis for acute ischemic stroke in a community-based approachStroke199829154415499707190
   PubMed Web of Science ®Google Scholar
• KatzanILFurlanAJLloydLEUse of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experienceJAMA20002831151115810703777
   PubMed Web of Science ®Google Scholar
• WangSLPanWHLeeMCChengSPChangMCPredictors of survival among elders suffering strokes in Taiwan: observation from a nationally representative sampleStroke2000312354236011022063
   PubMed Web of Science ®Google Scholar
• AlbersGWBatesVEClarkWMBellRVerroPHamiltonSAIntravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) studyJAMA20002831145115010703776
   PubMed Web of Science ®Google Scholar
• Lopez-YunezAMBrunoAWilliamsLSYilmazEZurruCBillerJProtocol violations in community-based rTPA stroke treatment are associated with symptomatic intracerebral hemorrhageStroke200132121611136907
   PubMed Web of Science ®Google Scholar
• GrottaJCBurginWSEl-MitwalliAIntravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000Arch Neurol2001582009201311735774
   PubMed Web of Science ®Google Scholar
• KoenneckeHCNohrRLeistnerSMarxPIntravenous tPA for ischemic stroke team performance over time, safety, and efficacy in a single-center, 2-year experienceStroke2001321074107811340212
   PubMed Web of Science ®Google Scholar
• BravataDMKimNConcatoJKrumholzHMBrassLMThrombolysis for acute stroke in routine clinical practiceArch Intern Med20021621994200112230423
   PubMed Web of Science ®Google Scholar
• KatzanILHammerMDFurlanAJHixsonEDNadzamDMQuality improvement and tissue-type plasminogen activator for acute ischemic stroke: a Cleveland updateStroke20033479980012624312
   PubMed Web of Science ®Google Scholar